Close

Hematopoietic Cell Transplantation for Autoimmune Diseases and Miscellaneous Indications

Number: 0606



Policy
  1. Aetna considers hematopoietic cell transplantation (autologous or allogeneic) experimental and investigational for any of the following autoimmune diseases (not an all-inclusive list) because its effectiveness for these indications has not been established. 
     
    1. Autoimmune cytopenia (e.g., autoimmune hemolytic anemia, Evans syndrome, and idiopathic thrombocytopenic purpura)
    2. Celiac disease
    3. Chronic inflammatory demyelinating polyradiculopathy
    4. Crohn's disease
    5. Dermatomyositis
    6. Juvenile rheumatoid arthritis
    7. Multiple sclerosis
    8. Neuromyelitis optica
    9. Polymyositis
    10. Rheumatoid arthritis
    11. Systemic lupus erythematosus
    12. Systemic sclerosis
    13. Systemic vasculitis
    14. Ulcerative colitis
       
  2. Aetna considers hematopoietic cell transplantation (autologous or allogeneic) experimental and investigational for any of the following miscellaneous conditions (not an all-inclusive list) because its effectiveness for these indications has not been established. 
     
    1. Age-related macular degeneration
    2. Amyotrophic lateral sclerosis
    3. Diabetes mellitus (type I)
    4. Essential thrombocythemia
    5. Polycythemia vera
    6. Recessive dystrophic epidermolysis bullosa
    7. Retinitis pigmentosa
    8. Thrombotic thrombocytopenic purpura
       
  3. Aetna considers the use of mesenchymal stem cells in hematopoietic stem cell transplantation experimental and investigational for the treatment of autoimmune diseases and selected indications listed in policy statement II.
Background

Autoimmune Diseases:

Autoimmune diseases (ADs) include a heterogeneous group of immune-mediated disorders that are responsive to suppression or modulation of the immune system.  Some common ADs are multiple sclerosis (MS), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE).  The prevalence of ADs in the United States is estimated to be approximately 2 %.  In particular, MS afflicts about 350,000 people in the United States, while RA and SLE affects 0.5 to 1.0 % and 0.05 % of Americans, respectively.  These diseases are often characterized by chronic, painful and debilitating courses that warrant aggressive therapy.  For some patients with severe, relapsing/refractory cases, conventional therapy may not be satisfactory.

High-dose chemotherapy (HDC) and bone marrow/peripheral stem cell transplantation (autologous or allogeneic) has been studied for the treatment of severe ADs.  The notion of employing HDC and bone marrow/peripheral stem cell transplant to treat AD is based on encouraging results in experimental animals and from serendipitous reports of patients with both ADs and malignancies who were allotransplanted for the latter.  High- dose chemotherapy and bone marrow/peripheral stem cell transplant has been tried for patients with ADs who are refractory to standard therapies and are at high-risk of subsequent morbidity and mortality.  Multiple sclerosis, RA, SLE, and systemic sclerosis are the ADs that have been most commonly treated by this procedure.  Although early findings are promising, the number of patients treated is limited, and only short-term follow-up is available.  Furthermore, the mechanism of improvement or stabilization is unclear, and the procedure has the potential for life-threatening toxicity.

A review (Bingham et al, 2000) stated that autologous stem cell transplantation is starting to be examined as a potential therapy for severe, refractory ADs including neurological, rheumatological, and hematological diagnoses.  Increasing numbers of cases are now reported in the scientific literature.  Data from all transplanted patients are being collated in a centralized register by the European Group for Blood and Marrow Transplantation and the European League against Rheumatism to ensure effective assessment of the safety and effectiveness of this promising procedure.  Thus far, results have been encouraging; however, they need to be confirmed by well-designed randomized, controlled studies in view of the well-known difficulty of judging objectively the effect of a treatment in patients with these diseases.  Optimization of mobilization, conditioning regimen, as well as graft manipulation is needed to maximize effectiveness without increasing mortality and morbidity.  The use of maintenance therapy after autologous stem cell transplantation to prevent relapse needs to be investigated.  Furst (2000) noted that stem cell transplantation for the treatment of systemic sclerosis is showing some apparent effectiveness, but its use is only in the pilot stages.

Witkowska et al (2014) stated that autoimmune connective tissue diseases (ACTDs) are heterogeneous disorders associated with different manifestations, clinical course of disease and prognosis among patients.  Although recent advances in understanding the pathogenesis have led to major progress in target-oriented therapy, they still remain incurable.  Novel biological drugs, cellular therapy and HSCT are real hopes for treatment development in the future.  The concept of both autologous and allogeneic HSCT in children with autoimmune diseases is developing energetically since 1996, when the first HSCT was performed.  Nowadays, after 17 years of clinical experience, both types of HSCT remain attractive and powerful salvage methods of treatment.  However, there are still many doubts and unclear issues, which need further investigation.  These investigators provided an overview of the knowledge concerning actual data on HSCT in a pediatric group of patients with different ACTDs, focused on juvenile idiopathic arthritis (JIA), SLE and systemic sclerosis.

Age-Related Macular Degeneration:

Du et al (2011) stated that there is currently no Food and Drug Administration-approved therapy for treating patients with geographic atrophy, a late stage of age-related macular degeneration (AMD).  Cell transplantation has the potential to restore vision in these patients.  These researchers discussed how recent advancement in induced pluripotent stem (iPS) cells provides a promising therapy for GA treatment.  Recent advances in stem cell biology have demonstrated that it is possible to derive iPS cells from human somatic cells by introducing re-programming factors.  Human retinal pigment epithelium (RPE) cells and photoreceptors can be derived from iPS cells by defined factors.  Studies show that transplanting these cells can stabilize or recover vision in animal models.  However, cell derivation protocols and transplantation procedures still need to be optimized.  Much validation has to be done before clinical-grade, patient-derived iPS can be applied for human therapy.  For now, RPE cells and photoreceptors derived from patient-specific iPS cells can serve as a valuable tool in elucidating the mechanism of pathogenesis and drug discovery for AMD.

Huang et al (2011) noted that retinal degenerative diseases that target photoreceptors or the adjacent RPE affect millions of people worldwide.  Retinal degeneration is found in many different forms of retinal diseases including retinitis pigmentosa, AMD, diabetic retinopathy, cataracts, and glaucoma.  Effective treatment for retinal degeneration has been widely investigated.  Gene-replacement therapy has been shown to improve visual function in inherited retinal disease.  However, this treatment was less effective with advanced disease.  Stem cell-based therapy is being pursued as a potential alternative approach in the treatment of retinal degenerative diseases.

Schwartz et al (2012) stated that it has been 13 years since the discovery of human embryonic stem cells (hESCs).  These researchers provided the first description of hESC-derived cells transplanted into human patients.  They started 2 prospective clinical studies to establish the safety and tolerability of subretinal transplantation of hESC-derived retinal pigment epithelium (RPE) in patients with Stargardt's macular dystrophy and dry AMD -- the leading cause of blindness in the developed world.  Pre-operative and post-operative ophthalmic examinations included visual acuity, fluorescein angiography, optical coherence tomography, and visual field testing.  The authors concluded that hESC-derived RPE cells showed no signs of hyper-proliferation, tumorigenicity, ectopic tissue formation, or apparent rejection after 4 months.  They stated that continued follow-up and future study is needed.  The ultimate therapeutic goal will be to treat patients earlier in the disease processes, potentially increasing the likelihood of photoreceptor and central visual rescue.

Amyotrophic Lateral Sclerosis:

Glass et al (2012) advances in stem cell biology have generated intense interest in the prospect of transplanting stem cells into the nervous system for the treatment of neurodegenerative diseases.  These researchers reported the results of an ongoing phase I trial of intra-spinal injections of fetal-derived neural stems cells in patients with amyotrophic lateral sclerosis (ALS).  This is a first in-human clinical trial with the goal of assessing the safety and tolerability of the surgical procedure, the introduction of stem cells into the spinal cord, and the use of immunosuppressant drugs in this patient population.  A total of 12 patients received either 5 unilateral or 5 bilateral (10 total) injections into the lumbar spinal cord at a dose of 100,000 cells/injection.  All patients tolerated the treatment without any long-term complications related to either the surgical procedure or the implantation of stem cells.  Clinical assessments ranging from 6 to 18 months after transplantation demonstrated no evidence of acceleration of disease progression due to the intervention.  One patient has shown improvement in his clinical status, though these data must be interpreted with caution since this trial was neither designed nor powered to measure treatment efficacy.  These results allow the authors to report success in achieving the phase I goal of demonstrating safety of this therapeutic approach.  Based on these positive results, the authors can now advance this trial by testing intra-spinal injections into the cervical spinal cord, with the goal of protecting motor neuron pools affecting respiratory function, which may prolong life for patients with ALS.

Martinez et al (2012) stated that ALS is characterized by the selective death of motor neurons.  Stem cells have been proposed as a potential therapeutic strategy.  These researchers described the safety of stem cell transplantation into the frontal motor cortex to improve upper motor neuron function.  A total of 67 patients with definite ALS were included.  After giving their informed consent, the patients underwent magnetic resonance imaging, functional rating, pulmonary function test, and laboratory tests.  Their bone marrow was stimulated with daily filgrastim (300 μg) given subcutaneously for 3 days.  Peripheral blood mononuclear cells were obtained by leukapheresis.  Isolated CD133+ stem cells were suspended in 300 μl of the patient's cerebrospinal fluid and implanted into the motor cortex.  Adverse events were recorded at each step of the procedure and were classified according to the Common Terminology Criteria for Adverse Events v3.0.  The survival at 1 year was 90 % after transplantation with a mean long-term survival rate of 40.17 months from diagnosis.  The most common adverse events were in grades I to II and involved transient skin pain (19.5 % of patients) attributed to the insertion of the Mahurkar catheter into the subclavian vein, minor scalp pain (15.9 %), and headache (12.2 %) from the surgical procedure.  Several patients (1.5 % to 4.5%) reported diverse grade I adverse events.  There were 2 deaths, 1 considered to be associated with the procedure (1.5 %) and the other associated with the disease.  Autologous stem cell transplantation into the frontal motor cortex is safe and well-tolerated by patients.  Moreover, they stated that further controlled studies are needed to define the efficacy of this procedure.

Thomsen et al (2014) noted that while the genetics of ALS are becoming more understood in familial cases, the mechanisms underlying disease pathology remain unclear and there are no effective treatment options.  Without understanding what causes ALS it is difficult to design treatments.  However, in recent years stem cell transplantation has emerged as a potential new therapy for ALS patients.  While motor neuron replacement remains a focus of some studies trying to treat ALS with stem cells, there is more rationale for using stem cells as support cells for dying motor neurons as they are already connected to the muscle.  This could be through reducing inflammation, releasing growth factors, and other potential less understood mechanisms.  Prior to moving into patients, stringent pre-clinical studies are required that have at least some rationale and effectiveness in animal models and good safety profiles.  However, given the poor understanding of what causes ALS and whether stem cells may ameliorate symptoms, there should be a push to determine cell safety in pre-clinical models and then a quick translation to the clinic where patient trials will show if there is any effectiveness.  The authors provided a critical review of current clinical trials using either MSCs or neural stem cells to treat ALS patients.  Pre-clinical data leading to these trials, as well as those in development were also evaluated in terms of mechanisms of action, validity of conclusions and rationale for advancing stem cell treatment strategies for ALS.

Chronic Inflammatory Demyelinating Polyradiculopathy:

Snowden et al (2012) provided revised and updated guidelines of the European Group for Blood and Marrow Transplantation (EBMT) for both the current application and future development of HSCT in ADs in relation to the benefits, risks and health economic considerations of other modern treatments.  These investigators listed sibling donor and well-matched unrelated donor as generally not recommended for chronic inflammatory demyelinating polyradiculopathy and neuromyelitis optica, among many ADs.  They emphasized a need for prospective interventional and non-interventional studies, where feasible, along with systematic data reporting, in accordance with EBMT policies and procedures.

Press et al (2014) noted that only 70 to 80 % of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) respond satisfactorily to the established first-line immunomodulatory treatments.  Autologous HSCT (AHSCT) has been performed as a last treatment resort in a few therapy-refractory cases with CIDP.  These researchers described the results of AHSCT in 11 consecutive Swedish patients with therapy-refractory CIDP with a median follow-up time of 28 months.  Case data were gathered retrospectively for AHSCT treatments in 11 patients with CIDP refractory to the first-line immunomodulatory treatments, intravenous high-dose immunoglobulin, corticosteroids and plasma exchange and to 1 or more second-line treatments used in 10 of the 11 patients.  The median Inflammatory Neuropathy Cause and Treatment (INCAT) score within 1 month prior to AHSCT was 6 and the Rankin score 4.  Total INCAT and Rankin scores improved significantly within 2 to 6 months after AHSCT and continued to do so at last follow-up.  The motor action potential amplitudes (CMAP) improved already within 4 months (median) after AHSCT; 3 of the 11 patients relapsed during the follow-up period, requiring re-transplantation with AHSCT in 1; 8 of the 11 patients maintained drug-free remission upon last follow-up.  Autologous HSCT was safe but on the short-term associated with a risk of cytomegalovirus (CMV) and Epstein-Barr virus re-activation, CMV disease, hemorrhagic cystitis and pancreatitis.  The authors concluded that these findings though hampered by the limited number of patients and the lack of a control group suggested AHSCT to be effective in therapy-refractory CIDP, with a manageable complication profile.  They stated that confirmation of these results is needed through RCTs.

Crohn's Disease:

Leung and associates (2006) reviewed the evidence regarding the use of HCT for the treatment of Crohn's disease (CD).  A Medline search (1970 to 2005) was performed using the keywords -- bone marrow transplant, stem cell, hematopoietic cell, Crohn's disease and inflammatory bowel disease.  These researchers identified 1 case in which a patient developed CD following an allogeneic HCT from a sibling suffering with CD.  Evidence for transfer of the genetic predisposition to develop CD was also identified with report of a patient that developed severe CD following an allogeneic HCT.  Following HCT it was found that the donor (that had no signs or symptoms of CD) and the recipient had several haplotype mismatches in HLA class III genes in the IBD3 locus including a polymorphism of NOD2/CARD15 that has been associated with CD.  A total of 33 published cases of patients with CD who underwent either autologous or allogeneic HCT were identified.  At the time of publication 29 of these 33 patients were considered to be in remission.  The median follow-up time was 7 years, and 20 months for allogeneic and autologous HCT, respectively.  For patients who underwent HCT primarily for treatment of their CD there have been no mortalities related to transplant complications.  The authors concluded that these preliminary data suggested that both allogeneic and autologous HCT may be effective in inducing remission in refractory CD.  This supports the hypothesis that the hematolymphatic cells play a key role in CD and that re-setting of the immune system may be a critical approach in the management or cure of CD.

Al-toma et al (2007) reported on the feasibility, safety, and effectiveness of ASCT in patients with refractory celiac disease with aberrant T cells (RCD type II).  A total of 13 patients with RCD type II were evaluated.  Seven patients (3 women, 4 men, mean age of 61.5 years [range of  51 to 69 years]) underwent transplantation.  After conditioning with fludarabine and melphalan, ASCT was performed.  Patients were monitored for response, adverse effects, and hematopoietic reconstitution.  All 7 patients completed the mobilization and leukapheresis procedures successfully and subsequently underwent conditioning and transplantation.  Engraftment occurred in all patients. No major non-hematological toxicity or transplantation-related mortality was observed.  There was a significant reduction in the aberrant T cells in duodenal biopsies associated with improvement in clinical well-being and normalization of hematological and biochemical markers (mean follow-up of 15.5 months; range of  7 to 30 months).  One patient died 8 months after transplantation from progressive neuro-celiac disease.  The authors concluded that these preliminary results showed that HDC followed by ASCT seems feasible and safe and might result in long-term improvement of patients with RCD type II whose condition did not respond promptly to available drugs.

Kotlarz et al (2012) examined heterogeneity among patients with very early onset inflammatory bowel disease (IBD), its mechanisms, and the use of allogeneic hematopoietic stem cell transplantation (HSCT) to treat this disorder.  These investigators analyzed 66 patients with early onset IBD (younger than 5 years of age) for mutations in the genes encoding IL-10, IL-10R1, and IL-10R2. IL-10R deficiency was confirmed by functional assays on patients' peripheral blood mononuclear cells (immunoblot and enzyme-linked immunosorbent assay analyses).  They assessed the therapeutic effects of standardized allogeneic HSCT.  Using a candidate gene sequencing approach, these researchers identified 16 patients with IL-10 or IL-10R deficiency: 3 patients had mutations in IL-10, 5 had mutations in IL-10R1, and 8 had mutations in IL-10R2.  Refractory colitis became manifest in all patients within the first 3 months of life and was associated with perianal disease (16 of 16 patients).  Extra-intestinal symptoms included folliculitis (11 of 16) and arthritis (4 of 16).  Allogeneic HSCT was performed in 5 patients and induced sustained clinical remission with a median follow-up time of 2 years.  In-vitro experiments confirmed reconstitution of IL-10R-mediated signaling in all patients who received the transplant.  The authors concluded that they identified loss of function mutations in IL-10 and IL-10R in patients with very early onset IBD.  These findings indicated that infantile IBD patients with perianal disease should be screened for IL-10 and IL-10R deficiency and that allogeneic HSCT can induce remission in those with IL-10R deficiency. 

In an editorial that accompanied the study by Koltarz et al, Muise and colleagues (2012) explained that the short-term results of this small series should be interpreted with caution.  The editorialists noted that “This study also reports the outcomes of 5 patients after hematopoietic stem cell transplantation (HSCT) with 2-year follow-up on 4 patients.   The authors used a highly immunosuppressive conditioning regimen that also resulted in depletion of myeloid cells including dendritic cells in conjunction with intense gut decolonization.  HSCT in this patient population was remarkably well tolerated and led to complete clinical remission in 4 out of 5 patients.  Although successful, it will be interesting to determine whether HSCT will result in a permanent “cure” for the colonic, joint, and skin disease in patients with IL-10RB mutations, because this receptor is widely expressed in these tissues and presumably the deficiency would persist after HSCT.   Variable results in HSCT ability to establish long-term remission in adult-onset IBD patients (reviewed by Anderson et al) points to cautious interpretation of these promising short-term HSCT results.  This study also leads to another important question regarding the role of HSCT in all infantile IBD.  As the authors correctly point out, there is a strong possibility that some infant and VEO-IBD patients may have gene defects in the non-hematopoietic cells, including epithelial barrier genes and, therefore, HSCT for all infantile IBD cannot be recommended at this time, unless a hematopoietic gene mutation that is functionally linked to disease can be identified”.

The National Institute for Health and Clinical Excellence’s clinical guideline on “Crohn's disease: Management in adults, children and young people” (NICE, 2012) does not mention the use of stem cell transplantation as a therapeutic option.  Furthermore, a RCT on the use of autologous stem cell transplantation for CD is currently underway. http://clinicaltrials.gov/ct2/show/NCT00297193.

Al-toma et al (2014) stated that both, autologous and allogeneic HSCT can be used to cure or ameliorate a variety of malignant and non-malignant diseases.  The rationale behind this strategy is based on the concept of immunoablation using HDC, with subsequent regeneration of naive T-lymphocytes derived from re-infused hematopoietic progenitor cells.  In addition, the use of HSCT allows for the administration of HDC (whether or not combined with immunomodulating agents such as anti-thymocyte globulin) resulting in a prompt remission in therapy-refractory patients.  These researchers provided an update of the major areas of successful uses of HSCT in non-malignant gastro-intestinal disorders.  A Medline search has been conducted and all relevant published data were analyzed.  Hematopoietic stem cell transplantation has been proved successful in treating refractory CD.  Patients with refractory celiac disease type II and a high risk of developing enteropathy associated T-cell lymphoma have shown promising improvement.  Data concerning HSCT and mesenchymal SCT in end-stage chronic liver diseases are encouraging.  In refractory autoimmune gastro-intestinal diseases HDC followed by HSCT seems feasible and safe and might result in long-term improvement of disease activity.  Moreover, they stated that mesenchymal SCT for a selected group of CD is promising and may represent a significant therapeutic alternative in treating fistulas in CD.

Diabetes Mellitus:

In a prospective phase I/II study, Voltarelli and co-workers (2007) examined the safety and metabolic effects of high-dose immunosuppression followed by autologous non-myeloablative hematopoietic stem cell transplantation (AHST) in newly diagnosed type 1 diabetes mellitus (DM).  A total of 15 patients with type 1 DM (aged 14 to 31 years) diagnosed within the previous 6 weeks by clinical findings and hyperglycemia and confirmed with positive antibodies against glutamic acid decarboxylase were included.  Patients with previous diabetic ketoacidosis were excluded after the first patient with diabetic ketoacidosis failed to benefit from AHST.  Hematopoietic stem cells were mobilized with cyclophosphamide (2.0 g/m2) and granulocyte colony-stimulating factor (10 microg/kg per day) and then collected from peripheral blood by leukapheresis and cryopreserved.  The cells were injected intravenously after conditioning with cyclophosphamide (200 mg/kg) and rabbit anti-thymocyte globulin (4.5 mg/kg).  Main outcome measures were morbidity and mortality from transplantation and temporal changes in exogenous insulin requirements (daily dose and duration of usage).  Secondary end points included serum levels of hemoglobin A1c, C-peptide levels during the mixed-meal tolerance test, and anti-glutamic acid decarboxylase antibody titers measured before and at different times following AHST.  During a 7- to 36-month follow-up (mean of 18.8 months), 14 patients became insulin-free (1 for 35 months, 4 for at least 21 months, 7 for at least 6 months; and 2 with late response were insulin-free for 1 and 5 months, respectively).  Among those, 1 patient resumed insulin use 1 year after AHST.  At 6 months after AHST, mean total area under the C-peptide response curve was significantly greater than the pre-treatment values, and at 12 and 24 months it did not change.  Anti-glutamic acid decarboxylase antibody levels decreased after 6 months and stabilized at 12 and 24 months.  Serum levels of hemoglobin A(1c) were maintained at less than 7 % in 13 of 14 patients.  The only acute severe adverse effect was culture-negative bilateral pneumonia in 1 patient and late endocrine dysfunction (hypothyroidism or hypogonadism) in 2 others.  There was no mortality.  The authors noted that high-dose immunosuppression and AHST were performed with acceptable toxicity in a small number of patients with newly diagnosed type 1 DM. With AHST, beta cell function was increased in all but 1 patient and induced prolonged insulin independence in the majority of the patients.  They stated that further follow-up is needed to confirm the duration of of insulin independence and the mechanisms of action of the procedure.  Furthermore, randomized controlled studies and more biological studies are needed to confirm the role of this procedure in changing the natural history of type 1 DM and to assess the contribution of hematopoietic stem cells to this change.

Multiple Sclerosis:

A recent study (Mancardi et al, 2001) on autologous hematopoietic stem cell (ASCT) transplantation for the treatment of patients with rapidly evolving secondary progressive MS concluded that the final impact of this procedure on disease course remains to be established.  In a study (Verburg et al, 2001) to evaluate the effectiveness of HDC followed by ASCT in the treatment of patients with refractory, progressively erosive RA, the authors concluded that there is a need for randomized clinical trials (RCTs).  Tyndall (2001) stated that randomized, prospective controlled phase III trials are needed to ascertain the effectiveness of ASCT following immunoablation for the treatment of SLE, however, more phase I and II data is needed to plan the optimal protocol.  An assessment by the BlueCross BlueShield Association Technology Evaluation Center (2001) concluded that there is insufficient evidence on health outcomes of the effect of stem cell transplant in autoimmune disease.

In a phase I/II study, Burt and colleagues (2009) examined the effects of autologous non-myeloablative hemopoietic stem cell transplantation in relapsing-remitting MS.  Eligible patients had relapsing-remitting MS, attended Northwestern Memorial Hospital, and despite treatment with interferon beta had had 2 corticosteroid-treated relapses within the previous 12 months, or 1 relapse and gadolinium-enhancing lesions seen on MRI and separate from the relapse.  Peripheral blood hemopoietic stem cells were mobilized with 2 g/m2 cyclophosphamide and 10 microg/kg per day filgrastim.  The conditioning regimen for the hemopoietic stem cells was 200 mg/kg cyclophosphamide and either 20 mg alemtuzumab or 6 mg/kg rabbit anti-thymocyte globulin.  Primary outcomes were progression-free survival and reversal of neurological disability at 3 years post-transplantation.  These researchers also investigated the safety and tolerability of autologous non-myeloablative hemopoietic stem cell transplantation.  A total of 21 patients were treated.  Engraftment of white blood cells and platelets was on median day 9 (range of day 8 to 11) and patients were discharged from hospital on mean day 11 (range of day 8 to 13).  One patient had diarrhea due to clostridium difficile and 2 patients had dermatomal zoster.  Two of the 17 patients receiving alemtuzumab developed late immune thrombocytopenic purpura that remitted with standard therapy.  A total of 17 of 21 patients (81 %) improved by at least 1 point on the Kurtzke expanded disability status scale (EDSS), and 5 patients (24 %) relapsed but achieved remission after further immunosuppression.  After a mean of 37 months (range of 24 to 48 months), all patients were free from progression (no deterioration in EDSS score), and 16 were free of relapses.  Significant improvements were noted in neurological disability, as determined by EDSS score (p < 0.0001), neurological rating scale score (p = 0.0001), paced auditory serial addition test (p = 0.014), 25-foot walk (p < 0.0001), and quality of life, as measured with the short form-36 questionnaire (p < 0.0001).  The authors concluded that non-myeloablative autologous hemopoietic stem cell transplantation in patients with relapsing-remitting MS reverses neurological deficits, but these results need to be confirmed in a randomized trial.

Tappenden and colleagues (2010) stated that therapeutic options for secondary progressive MS (SPMS) are limited.  Mitoxantrone is routinely used to stabilize disease progression; however, evolving evidence suggests clinical benefit from intensive treatment with autologous hematopoietic stem cell transplantation (HSCT).  Given differences in cost and outcomes, preliminary cost-effectiveness studies are warranted if this approach is to be developed for more widespread application in SPMS.  These researchers developed a decision-analytic Markov model to explore the potential cost-effectiveness of autologous HSCT versus mitoxantrone in SPMS, using patient-level data from registry sources.  The model evaluates the lifetime costs and health outcomes associated with disability progression and relapse.  Sensitivity analyses were undertaken to examine the uncertainty surrounding cost-effectiveness outcomes.  In the absence of RCT evidence, conditions for comparative analysis were not ideal.  Under optimistic assumptions, HSCT is estimated to cost below 3,000 pounds per quality adjusted life year gained.  However, when a strict 6-month sustained progression rule is adopted, HSCT may be less effective and more expensive than mitoxantrone.  The model results were sensitive to reducing procedural costs and HSCT-related mortality.  The authors concluded that HSCT could potentially achieve an acceptable level of cost-effectiveness.  However, caution should be exercised as large, high-quality RCTs comparing HSCT versus mitoxantrone are needed to validate these findings.  Further analyses are necessary to examine the economic value of HSCT for the treatment of rapidly progressing, relapsing-remitting and aggressive forms of MS.

Atkin (2010) noted that MS is the leading autoimmune indication for autologous HSCT (aHSCT).  Patient selection criteria and transplant interventions have been refined through a series of cohort and registry studies.  High- and low-intensity chemotherapy-based conditioning regimens have been used, creating trade-offs between toxicity and effectiveness.  Total body irradiation has been associated with greater toxicity and poor outcomes.  Autologous HSCT stops MS relapses and lessens the disability in malignant MS, which otherwise rapidly incapacitates patients.  Better responses occur in progressive MS earlier in the disease when it has a more inflammatory nature.  Autologous HSCT prevents further disability in many patients, but some actually recover from their infirmities.  Current regimens and supportive care result in very low morbidity and mortality.  Patients with MS experience unique complications in addition to the expected toxicities.  Cytokines used alone for stem-cell mobilization may induce MS flares but are safe to be used in combination with steroids or cytotoxic agents.  Urinary tract infections, herpes virus reactivation and an engraftment syndrome may occur early after aHSCT.  Rarely secondary autoimmune diseases have been reported late after HSCT.  Increasing experience in caring for patients with MS has reduced the frequency and severity of toxicity.  Conceived as an opportunity to "reboot" a tolerant immune system, aHSCT is successful in treating patients with MS that is refractory to conventional immunomodulatory drugs.  It is noted that patients are unlikely to benefit from aHSCT if they have had longstanding MS or disabilities that have advanced to the point where they are wheelchair bound.  Furthermore, previous MS treatments can potentially impact aHSCT (e.g., interferon may impair stem cell collection, natalizumab may increase the risk of opportunistic infections, and mitoxantrone could cause myelodysplasia).  Moreover, the author stated that aHSCT for MS is still controversial.  It has not entered widespread clinical use because of its perceived high mortality, high cost, and competition from new pharmaceutical agents.  The author noted that a direct comparison of aHSCT with conventional treatments in multi-center randomized controlled trials and publication of 5 to 10 years long-term follow-up data from cohort studies and international registries are a necessary step in further defining the role of aHSCT in the management of MS.

At present, there are no well-designed randomized controlled clinical trials of stem cell transplantation in autoimmune diseases in the peer-reviewed published medical literature.  Such studies are necessary to determine whether stem cell transplantation improves clinical outcomes of autoimmune diseases.  In addition, where stem cell transplantation is used with myeloablative chemotherapy of autoimmune diseases, the efficacy of stem cell transplantation in restoring hematopoiesis should be compared with administration of myelopoietic growth factors (G-CSF and GM-CSF).

The position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop on "Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease" (Griffith et al, 2005) concluded that "[a] rationale clearly exists for exploring the therapeutic and curative potential of allogeneic HCT for severe autoimmune disease [systemic sclerosis, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, and autoimmune cytopenia].  Although safer allogeneic transplantation strategies have become available, experience is currently insufficient to allow reliable extrapolation of data on safety and risks from patients with malignancies to patients with autoimmune diseases.  It is recommended that planning be initiated for clinical trials to generate safety and efficacy data for allogeneic HCT [hematopoietic stem cell transplant] in patients with severe autoimmune diseases".

Rice and colleagues (2013) stated that MS is incurable, but stem-cell therapy might offer valuable therapeutic potential.  Efforts to develop stem-cell therapies for MS have been conventionally built on the principle of direct implantation of cells to replace oligodendrocytes, and therefore to regenerate myelin.  Recent progress in understanding of disease processes in MS include observations that spontaneous myelin repair is far more widespread and successful than was previously believed, that loss of axons and neurons is more closely associated with progressive disability than is myelin loss, and that damage occurs diffusely throughout the CNS in grey and white matter, not just in discrete, isolated patches or lesions.  These findings had introduced new and serious challenges that stem-cell therapy needs to overcome; the practical challenges to achieve cell replacement alone are difficult enough, but, to be useful, cell therapy for MS must achieve substantially more than the replacement of lost oligodendrocytes.  However, parallel advances in understanding of the reparative properties of stem cells -- including their distinct immunomodulatory and neuroprotective properties, interactions with resident or tissue-based stem cells, cell fusion, and neurotrophin elaboration -- offer renewed hope for development of cell-based therapies.  Moreover, the authors stated that these advances suggested avenues for translation of this approach not only for MS, but also for other common neurological and neurodegenerative diseases.

Burt et al (2015) determined the association of non-myeloablative HSCT with neurological disability and other clinical outcomes in patients with MS.  This study included case series of patients with relapsing-remitting MS (n = 123) or secondary-progressive MS (n = 28) (mean age of 36 years; range of 18 to 60 years; 85 women) treated at a single US institution between 2003 and 2014 and followed-up for 5 years.  Final follow-up was completed in June 2014.  Treatment with cyclophosphamide and alemtuzumab (22 patients) or cyclophosphamide and thymoglobulin (129 patients) followed by infusion of un-manipulated peripheral blood stem cells.  Primary end-point was reversal or progression of disability measured by change in the EDSS score of 1.0 or greater (score range of 0 to 10).  Secondary outcomes included changes in the Neurologic Rating Scale (NRS) score of 10 or greater (score range of 0 to 100), Multiple Sclerosis Functional Composite (MSFC) score, quality-of-life Short Form 36 questionnaire scores, and T2 lesion volume on brain magnetic resonance imaging scan.  Outcome analysis was available for 145 patients with a median follow-up of 2 years and a mean of 2.5 years.  Scores from the EDSS improved significantly from a pre-transplant median of 4.0 to 3.0 (interquartile range [IQR]: 1.5 to 4.0; n = 82) at 2 years and to 2.5 (IQR, 1.9 to 4.5; n = 36) at 4 years (p < 0.001 at each assessment).  There was significant improvement in disability (decrease in EDSS score of greater than or equal to 1.0) in 41 patients (50 %; 95 % CI: 39 % to 61 %) at 2 years and in 23 patients (64 %; 95 % CI: 46 % to 79 %) at 4 years.  Four-year relapse-free survival was 80 % and PFS was 87 %.  The NRS scores improved significantly from a pre-transplant median of 74 to 88.0 (IQR, 77.3 to 93.0; n = 78) at 2 years and to 87.5 (IQR, 75.0 to 93.8; n = 34) at 4 years (p < 0.001 at each assessment).  The median MSFC scores were 0.38 (IQR, -0.01 to 0.64) at 2 years (p < 0.001) and 0.45 (0.04 to 0.60) at 4 years (p = 0.02).  Total quality-of-life scores improved from a mean of 46 (95 % CI: 43 to 49) pre-transplant to 64 (95 % CI: 61 to 68) at a median follow-up of 2 years post-transplant (n = 132) (p < 0.001).  There was a decrease in T2 lesion volume from a pre-transplant median of 8.57 cm3 (IQR, 2.78 to 22.08 cm3) to 5.74 cm3 (IQR, 1.88 to 14.45 cm3) (p < 0.001) at the last post-transplant assessment (mean follow-up of 27 months; n = 128).  The authors concluded that among patients with relapsing-remitting MS, non-myeloablative HSCT was associated with improvement in neurological disability and other clinical outcomes.  They stated that these preliminary findings from this uncontrolled study require confirmation in randomized trials.

The major drawbacks of this study were: (i) it was a single-center study, which may introduce the possibility of bias, (ii) a number of patients were treated on a compassionate basis, rather than on the study protocol, (iii) improvement in function in patients with MS may be in part a consequence of continuing recovery from earlier relapses, (iv) long-term follow-up (i.e., greater than or equal to 4 years) was not available for a substantial proportion of patients, and (v) this was an observational cohort study without a control group.

In an editorial that accompanied the afore-mentioned study, Hauser (2015) stated that (i) autologous HSCT does not appear to be effective against established progressive forms of MS and, absence of new data, additional trials of these protocols are probably not indicated for patients with progressive MS, (ii) immunosuppressive regimens that include HSCT appear to be effective against relapsing-remitting form of MS , at least over several years of observation.  However, it is by no means clear that the beneficial effects result from the infusion of stem cells rather than from the conditioning regimen.  Studies that delineate the role of HSCT specifically in improving outcomes relative to conditioning regimens alone are needed before this therapy should be deployed outside of the clinical research setting,  (iii) the mechanism of action of autologous HSCT in MS needs to be clarified, and (iv) very long follow-up periods are needed to meaningfully assess the role of HSCT in the treatment of MS.

In a multi-center, phase II clinical trial, Mancardi et al (2015) examined the effect of intense immunosuppression followed by AHSCT versus mitoxantrone (MTX) on disease activity measured by MRI in patients with MS.  Patients with secondary progressive or relapsing-remitting MS, with a documented increase in the last year on the EDSS, in spite of conventional therapy, and presence of 1 or more gadolinium-enhancing (Gd+) areas were included in this study.  Patients were randomized to receive intense immunosuppression (mobilization with cyclophosphamide and filgrastim, conditioning with carmustine, cytosine-arabinoside, etoposide, melphalan, and anti-thymocyte globulin) followed by AHSCT or MTX 20 mg every month for 6 months.  The primary end-point was the cumulative number of new T2 lesions in the 4 years following randomization.  Secondary end-points were the cumulative number of Gd+ lesions, relapse rate, and disability progression.  Safety and tolerability were also assessed; 21 patients were randomized and 17 had post-baseline evaluable MRI scans.  Autologous HSCT reduced by 79 % the number of new T2 lesions as compared to MTX (rate ratio 0.21, p = 0.00016).  It also reduced Gd+ lesions as well as the annualized relapse rate.  No difference was found in the progression of disability.  The authors concluded that intense immunosuppression followed by AHSCT is significantly superior to MTX in reducing MRI activity in severe cases of MS.  They stated that these results strongly support further phase III studies with primary clinical end-points.

Polycythemia Vera:

Polycythemia vera (PV) in children and adolescents is very rare.  Data on clinical and laboratory evaluations as well as on treatment modalities are sparse.  Cario and associates (2009) reported the long-term clinical course of a PV patient first diagnosed more than 40 years ago at age 12.  In addition, after a systematic review of the scientific medical literature, clinical and hematological data of 36 patients (17 males and 19 females) from 25 previous reports were summarized.  Three patients developed PV following antecedent hematological malignancies; Budd-Chiari syndrome was diagnosed in 7 patients indicating a particular risk of young patients of developing this disorder.  One patient presented with ischemic stroke, 1 patient with gangrene, and 3 patients with severe hemorrhage, 3 patients died from disease-related complications.  Hematocrit levels and platelet counts were not correlated with disease severity.  Leukocytosis greater than 15 x 10(9)/L was present in 9/35 patients and associated with a thromboembolic or hemorrhagic complication in 7 patients.  The few available data on molecular genetics and endogenous erythroid colony growth indicate changes comparable to those detectable in adult patients.  Treatment varied enormously.  It included aspirin, phlebotomy, hydroxycarbamide, busulfan, melphalan, pyrimethamine, and interferon-alpha.  Two patients successfully underwent stem cell transplantation.  The authors stated that it is currently impossible to treat an individual pediatric PV patient with an evidence-based regimen.

Tefferi and Vainchenker (2011) updated oncologists on pathogenesis, contemporary diagnosis, risk stratification, and treatment strategies in BCR-ABL1-negative myeloproliferative neoplasms, including PV, essential thrombocythemia (ET), and primary myelofibrosis (PMF).  Recent literature was reviewed and interpreted in the context of the authors' own experience and expertise.  Pathogenetic mechanisms in PV, ET, and PMF include stem cell-derived clonal myeloproliferation and secondary stromal changes in the bone marrow and spleen.  Most patients carry an activating JAK2 or MPL mutation and a smaller subset also harbors LNK, CBL, TET2, ASXL1, IDH, IKZF1, or EZH2 mutations; the precise pathogenetic contribution of these mutations is under investigation.  JAK2 mutation analysis is now a formal component of diagnostic criteria for PV, ET, and PMF, but its prognostic utility is limited.  Life expectancy in the majority of patients with PV or ET is near-normal and disease complications are effectively (and safely) managed by treatment with low-dose aspirin, phlebotomy, or hydroxyurea.  In PMF, survival and quality of life are significantly worse and current therapy is inadequate.  In ET and PV, controlled studies are needed to show added value and justify the risk of unknown long-term health effects associated with non-conventional therapeutic approaches (e.g., interferon-alfa).  The authors stated that the unmet need for treatment in PMF dictates a different approach for assessing the therapeutic value of new drugs (e.g., JAK inhibitors, pomalidomide) or allogeneic stem-cell transplantation.

Furthermore, Cancer Care Ontario's guidelines on the management of malignant thrombocytosis in Philadelphia chromosome-negative myeloproliferative disease (specifically ET or PV) (Matthews et al, 2008) as well as the National Health, Lung and Blood Institute's Diseases and Conditions Index on polycythemia vera (2011) do not list stem cell transplant as a therapeutic option.

 

Recessive Dystrophic Epidermolysis Bullosa:

Recessive dystrophic epidermolysis bullosa is an incurable, often fatal mucocutaneous blistering disease caused by mutations in COL7A1, the gene encoding type VII collagen (C7).  On the basis of pre-clinical data showing biochemical correction and prolonged survival in col7 −/− mice, Wagner et al (2010) hypothesized that allogeneic marrow contains stem cells capable of ameliorating the manifestations of recessive dystrophic epidermolysis bullosa in humans.  Between October 2007 and August 2009, these researchers treated 7 children who had recessive dystrophic epidermolysis bullosa with immuno-myeloablative chemotherapy and allogeneic stem-cell transplantation.  They assessed C7 expression by means of immunofluorescence staining and used transmission electron microscopy to visualize anchoring fibrils.  These investigators measured chimerism by means of competitive polymerase-chain-reaction assay, and documented blister formation and wound healing with the use of digital photography.  One patient died of cardiomyopathy before transplantation.  Of the remaining 6 patients, 1 had severe regimen-related cutaneous toxicity, with all having improved wound healing and a reduction in blister formation between 30 and 130 days after transplantation.  These researchers observed increased C7 deposition at the dermal-epidermal junction in 5 of the 6 recipients, albeit without normalization of anchoring fibrils.  Five recipients were alive 130 to 799 days after transplantation; 1 died at 183 days as a consequence of graft rejection and infection.  The 6 recipients had substantial proportions of donor cells in the skin, and none had detectable anti-C7 antibodies.  The authors concluded that increased C7 deposition and a sustained presence of donor cells were found in the skin of children with recessive dystrophic epidermolysis bullosa after allogeneic bone marrow transplantation.  They stated that further studies (with more objective methods to evaluate the frequency of blistering, larger patient cohorts, and longer follow-up periods) are needed to assess the long-term risks and benefits of such therapy in patients with this disorder.

Retinitis Pigmentosa:

Li et al (2012) stated that the U.S. Food and Drug Administration recently approved phase I/II clinical trials for embryonic stem (ES) cell-based retinal pigmented epithelium (RPE) transplantation, but this allograft transplantation requires life-long immunosuppressive therapy.  Autografts from patient-specific induced pluripotent stem (iPS) cells offer an alternative solution to this problem.  However, more data are required to establish the safety and effectiveness of iPS transplantation in animal models before moving iPS therapy into clinical trials.  This study examined the effectiveness of iPS transplantation in restoring functional vision in Rpe65(rd12)/Rpe65(rd12) mice, a clinically relevant model of RP.  Human iPS cells were differentiated into morphologically and functionally RPE-like tissue.  Quantitative real-time polymerase chain reaction (RT-PCR) and immunoblots confirmed RPE fate.  The iPS-derived RPE cells were injected into the subretinal space of Rpe65(rd12)/Rpe65(rd12) mice at 2 days post-natally.  After transplantation, the long-term surviving iPS-derived RPE graft co-localized with the host native RPE cells and assimilated into the host retina without disruption.  None of the mice receiving transplants developed tumors over their life-times.  Furthermore, electroretinography demonstrated improved visual function in recipients over the life-time of this RP mouse model.  The authors concluded that this study provided the first direct evidence of functional recovery in a clinically relevant model of retinal degeneration using iPS transplantation and supports the feasibility of autologous iPS cell transplantation for retinal and macular degenerations featuring significant RPE loss.

Rheumatoid Diseases:

Liu et al (2014) noted that the clinical management of autoimmune rheumatic diseases (ARD) has undergone significant changes in the last few decades, leading to remarkable improvements in clinical outcomes of many patients with mild to moderate ARD.  On the other hand, severe refractory ARD patients often have high morbidity and mortality.  Extensive basic research and clinical evidence has opened the door to new encouraging perspectives, such as the establishment of a role of HSCT in the strategic management of ARD.  Given the great heterogeneity of ARD, it is difficult to assign an optimal HSCT regimen to all ARD patients.  The authors concluded that HSCT remains a challenging mode of therapy in ARD patients from the standpoints of both safety and effectiveness.  As the clinical data of HSCT in ARD increases and as the understanding of stem cell biology and the downstream effects on the immune system increases, the future is promising for the development of optimal personalized HSCT regimens in ARD.

Systemic Lupus Sclerosus:

Loh et al (2007) stated that patients with cardiac dysfunction may be at increased risk of cardiac toxicity when undergoing HCT, which may preclude them from receiving this therapy.  Moreover, cardiac dysfunction is common in SLE patients.  While autologous HCT (auto-HCT) has been performed increasingly for SLE, its impact on cardiac function has not previously been evaluated.  Thus, these investigators performed a retrospective analysis of SLE patients who had undergone auto-HCT to determine the prevalence of significant cardiac involvement, and the impact of transplantation on this.  The records of 55 patients were reviewed, of which 13 were found to have abnormal cardiac findings on pre-transplant 2-dimensional echocardiography or multi-gated acquisition scan: impaired left ventricular ejection fraction (LVEF) (n = 6), pulmonary hypertension (n = 5), mitral valve dysfunction (n = 3) and large pericardial effusion (n = 1).  At a median follow-up of 24 months (8 to 105 months), there were no transplant-related or cardiac deaths.  With transplant-induced disease remission, all patients with impaired LVEF remained stable or improved; while 3 with symptomatic mitral valve disease similarly improved. Elevated pulmonary pressures paralleled activity of underlying lupus.  These data suggest that auto-HCT is feasible in selected patients with lupus-related cardiac dysfunction, and with control of disease activity, may improve.  The authors stated that the findings of this study warrant a prospective study with a larger cohort of SLE patients.  It is hoped that with further investigation, the selection of which patients with cardiac abnormalities would benefit from auto-HCT and justify the potential risk will be made clearer.

Song and colleagues (2011) examined the effectiveness and toxicity of autologous stem cell transplantation (auto-SCT) in patients with SLE (n = 17).  Peripheral blood stem cells were mobilized with cyclophosphamide (Cy) and granulocyte colony-stimulating factor.  After a conditioning regimen of Cy and anti-thymocyte globulin, stem cells was re-infused.  The probabilities of overall survival (OS) and progression-free survival (PFS) were used to assess the efficacy and adverse experiences, to detect the toxicities of the treatment.  The median follow-up time was 89 months (range of 33 to 110).  Probabilities of 7-year OS and PFS were 82.4 % +/- 9.2 % and 64.7 % +/- 11.6 %, respectively.  The principal adverse events included allergy, infection, elevation of liver enzymes, bone pain, and heart failure.  Two patients died due to severe pneumonia and heart failure at 33 and 64 months after transplantation, respectively.  The authors concluded that their 7-year follow-up results suggested that auto-SCT seemed beneficial for SLE patients.  Moreover, they stated that recruitment of more patients into multi-center, randomized, comparative studies versus conventional treatment of SLE is needed to evaluate the safety and effectiveness of auto-SCT.

Thrombotic Thrombocytopenic Purpura:

UpToDate reviews on “Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults” (Kaplan and George, 2013) does not mention the use of transplantation as a therapeutic option.

Ulcerative Colitis:

UpToDate reviews on “Management of severe ulcerative colitis” (Peppercorn and Farrell, 2013) and “Treatment of ulcerative colitis in children and adolescents” (Bousvaros et al, 2013) do not mention the use of transplantation as a therapeutic option.

Mesenchymal Stem Cells:

Wu and colleagues (2013) stated that mesenchymal stem cells (MSCs) have been shown to be effective in the management of graft-versus-host disease (GVHD) due to their immunomodulatory effects.  In addition to prevention and treatment of GVHD, many studies have demonstrated that MSCs can promote hematopoietic engraftment, accelerate lymphocyte recovery, reduce the risk of graft failure, and repair tissue damage in patients receiving HSCT.   Bone marrow (BM) has been considered as the traditional source of MSCs, and most of the knowledge concerning MSCs comes from BM studies.  However, BM-derived MSCs have several limitations for their clinical application.  Fetal-type MSCs can be isolated easier and proliferate faster in-vitro as well as possessing a lower immunogenicity.  Therefore, fetal-type MSCs, such as umbilical cord-derived MSCs, represent an excellent alternative source of MSCs.  Mesenchymal stem cells play multiple important roles in HSCT.  Nevertheless, several issues regarding their clinical application remain to be discussed, including the safety of use in humans, the available sources and the convenience of obtaining MSCs, the quality control of in vitro-cultured MSCs and the appropriate cell passages, the optimum cell dose, and the optimum number of infusions.  Furthermore, it is important to evaluate whether the rates of cancer relapse and infections increase when using MSCs for GVHD.  The authors concluded that there are still many questions regarding the clinical application of MSCs to HSCT that need to be answered, and further studies are needed.

Batsali et al (2013) noted that in recent years there seems to be an unbounded interest concerning MSCs.  This is mainly attributed to their exciting characteristics including long-term ex-vivo proliferation, multi-lineage potential and immunomodulatory properties.  In this regard MSCs emerge as attractive candidates for various therapeutic applications.  Mesenchymal stem cells were originally isolated from the BM and this population is still considered as the gold standard for MSC applications.  However, the BM has several limitations as source of MSCs, including MSC low frequency in this compartment, the painful isolation procedure and the decline in MSC characteristics with donor's age.  Thus, there is accumulating interest in identifying alternative sources for MSCs.  To this end MSCs obtained from the Wharton's Jelly (WJ) of umbilical cords (UC) have gained much attention over the last years since they can be easily isolated, without any ethical concerns, from a tissue which is discarded after birth.  Furthermore WJ-derived MSCs represent a more primitive population than their adult counterparts, opening new perspectives for cell-based therapies.  The authors provided an overview of the biology of WJ-derived UC-MSCs; and discussed the potential application of WJ-derived UC-MSCs for the treatment of cancer and immune mediated disorders, such as GVHD and SLE.

CPT Codes / HCPCS Codes / ICD-9 Codes
CPT codes not covered for indications listed in the CPB:
38204 Management of recipient hematopoietic progenitor cell donor search and cell acquisition
38205 Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic
38206 Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous
38207 - 38215 Bone marrow or stem cell services/procedures
38230 -38232 Bone marrow harvesting for transplantation; allogeneic or autologous
38240 Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor
38241     autologous transplantation
Other CPT codes related to the CPB:
86813 HLA typing; A, B or C, multiple antigens
86817 DR/DQ, multiple antigens
86821 lymphocyte culture, mixed (MLC)
86822 lymphocyte culture, primed (PLC)
86920 - 86923 Compatibility test each unit
HCPCS codes not covered for indications listed in the CPB:
S2140 Cord blood harvesting for transplantation, allogeneic
S2150 Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre- and post-transplant care in the global definition
ICD-9 codes not covered for indications listed in the CPB:
238.4 Polycythemia vera
249.00 - 250.93 Diabetes mellitus
283.0 Autoimmune hemolytic anemias
287.30 Primary thrombocytopenia unspecified (essential)
287.31 Immune thrombocytopenic purpura
287.32 Evans' syndrome
335.20 Amyotrophic lateral sclerosis
340 Multiple sclerosis
341.0 Neuromyelitis optica
357.81 Chronic inflammatory demyelinating polyneuritis
362.50 Macular degeneration (senile), [age related] unspecified
362.74 Pigmentary retinal dystrophy
446.6 Thrombotic microangiopathy
555.0 - 555.9 Regional enteritis
556.0 - 556.9 Ulcerative colitis
579.0 Celiac disease
710.0 Systemic lupus erythematosus
710.1 Systemic sclerosis
710.3 Dermatomyositis
710.4 Polymyositis
714.0 - 714.33 Rheumatoid arthritis
757.39 Other specified anomalies of skin [recessive dystrophic epidermolysis bullosa]
CPT Codes / HCPCS Codes / ICD-10 Codes
Information in the [brackets] below has been added for clarification purposes.   Codes requiring a 7th character are represented by "+":
ICD-10 codes will become effective as of October 1, 2015:
CPT codes not covered for indications listed in the CPB:
38204 Management of recipient hematopoietic progenitor cell donor search and cell acquisition
38205 Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic
38206 Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous
38207 - 38215 Bone marrow or stem cell services/procedures
38230 - 38232 Bone marrow harvesting for transplantation;allogeneic or autologous
38240 Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor
38241    autologous transplantation
Other CPT codes related to the CPB:
86813 HLA typing; A, B or C, multiple antigens
86817 DR/DQ, multiple antigens
86821 lymphocyte culture, mixed (MLC)
86822 lymphocyte culture, primed (PLC)
86920 - 86923 Compatibility test each unit
HCPCS codes not covered for indications listed in the CPB:
S2150 Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre- and post-transplant care in the global definition
ICD-10 codes not covered for indications listed in the CPB:
D45 Polycythemia vera
D47.3 Essential (hemorrhagic) thrombocythemia
D59.0 - D59.1 Autoimmune hemolytic anemia
D69.3 Immune thrombocytopenic purpura
D69.41 Evan's syndrome
E08.00 - E13.9 Diabetes mellitus
G12.21 Amyotrophic lateral sclerosis
G35 Multiple sclerosis
G36.0 Neuromyelitis optica [Devic]
G61.81 Chronic inflammatory demyelinating polyneuritis
H35.30 Unspecified macular degeneration (age-related)
H35.52 Pigmentary retinal dystrophy
K50.00 - K50.919 Crohn's disease [regional enteritis]
K51.00 - K51.919 Ulcerative colitis
K90.0 Celiac disease
M05.00 - M06.9 Rheumatoid arthritis
M31.1 Thrombotic microangiopathy
M32.10 - M32.9 Systemic lupus erythematosus (SLE)
M33.00 - M33.99 Dermatomyositis
M34.0 - M34.9 Systemic sclerosis [scleroderma]
M36.0 Dermato(poly)myositis in neoplastic disease
Q81.0 - Q81.9 Epidermolysis bullosa


The above policy is based on the following references:
    1. Mancardi GL, Saccardi R, Filippi M, et al. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology. 2001;57(1):62-68.
    2. Kozak T, Havrdova E, Pit'ha J, et al. Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis. Transplant Proc. 2001;33(3):2179-2181.
    3. Binks M, Passweg JR, Furst D, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: Procedure related mortality and impact on skin disease. Ann Rheum Dis. 2001;60(6):577-584.
    4. Tyndall A. Immunoablation and haemopoietic stem cell transplantation for severe autoimmune disease with special reference to systemic lupus erythematosus. Lupus. 2001;10(3):214-215.
    5. Verburg RJ, Sont JK, Vliet Vlieland TP, et al. High dose chemotherapy followed by autologous peripheral blood stem cell transplantation or conventional pharmacological treatment for refractory rheumatoid arthritis? A Markov decision analysis. J Rheumatol. 2001;28(4):719-727.
    6. Furst DE. The status of stem cell transplantation for rheumatoid arthritis: A rheumatologist's view. J Rheumatol Suppl. 2001;64:60-61.
    7. Jantunen E, Myllykangas-Luosujarvi R. Stem cell transplantation for treatment of severe autoimmune diseases: Current status and future perspectives. Bone Marrow Transplant. 2000;25(4):351-356.
    8. Comi G, Kappos L, Clanet M, et al. Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: A consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. BMT-MS Study Group. J Neurol. 2000;247(5):376-382.
    9. Bingham SJ, Snowden JA, Emery P. Autologous blood stem cell transplantation as therapy for autoimmune diseases. Ann Med. 2000;32(9):615-621.
    10. Marmont AM. New horizons in the treatment of autoimmune diseases: Immunoablation and stem cell transplantation. Annu Rev Med. 2000;51:115-134.
    11. Fassas A, Anagnostopoulos A, Kazis A, et al. Autologous stem cell transplantation in progressive multiple sclerosis -- an interim analysis of efficacy. J Clin Immunol. 2000;20(1):24-30.
    12. Traynor AE, Schroeder J, Rosa RM, et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: A phase I study. Lancet. 2000;356(9231):701-707.
    13. Brodsky RA, Petri M, Jones RJ. Hematopoietic stem cell transplantation for systemic lupus erythematosus. Rheum Dis Clin North Am. 2000;26(2):377-387, viii.
    14. Lowenthal RM, Graham SR. Does hemopoietic stem cell transplantation have a role in treatment of severe rheumatoid arthritis? J Clin Immunol. 2000;20(1):17-23.
    15. Furst DE. Rational therapy in the treatment of systemic sclerosis. Curr Opin Rheumatol. 2000;12(6):540-544.
    16. Nash RA. Prospects of stem cell transplantation in autoimmune diseases. J Clin Immunol. 2000;20(1):38-45.
    17. Tyndall A, Fassas A, Passweg J, et al. Autologous haematopoietic stem cell transplants for autoimmune disease -- feasibility and transplant-related mortality. Autoimmune Disease and Lymphoma Working Parties of the European Group for Blood and Marrow Transplantation, the European League Against Rheumatism and the International Stem Cell Project for Autoimmune Disease. Bone Marrow Transplant. 1999;24(7):729-734.
    18. Burt RK, Traynor A, Burns W. Hematopoietic stem cell transplantation of multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus. Cancer Treat Res. 1999;101:157-184.
    19. Snowden JA, Biggs JC, Milliken ST, et al. A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis. Arthritis Rheum. 1999;42(11):2286-2292.
    20. Burt RK, Traynor A. Hematopoietic stem cell therapy of autoimmune diseases. Curr Opin Hematol. 1998;5(6):472-477.
    21. Burt RK, Traynor AE, Pope R, et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood. 1998;92(10):3505-3514.
    22. Thomas ED. Pros and cons of stem cell transplantation for autoimmune disease. J Rheumatol Suppl. 1997;48:100-102.
    23. Snowden JA, Brooks PM, Biggs JC. Haemopoietic stem cell transplantation for autoimmune diseases. Br J Haematol. 1997;99(1):9-22.
    24. Jacobson DL, Gange SJ, Rose NR, et al. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84(3):223-243.
    25. Klippel JH. Systemic lupus erythematosus: Demographics, prognosis, and outcome. J Rheumatol Suppl. 1997;48:67-71.
    26. Hintzen RQ. Stem cell transplantation in multiple sclerosis: Multiple choices and multiple challenges. Mult Scler. 2002;8(2):155-160.
    27. Furst DE. Stem cell transplantation for autoimmune disease: Progress and problems. Curr Opin Rheumatol. 2002;14(3):220-224.
    28. Kozak T, Rychlik I. Developments in hematopoietic stem-cell transplantation in the treatment of autoimmune diseases. Isr Med Assoc J. 2002;4(4):268-271.
    29. BlueCross BlueShield Association (BCBSA), Technology Evaluation Center (TEC). High-dose lymphoablative therapy (HDLT) with or without stem-cell rescue for treatment of severe autoimmune diseases. TEC Assessment Program. Chicago, IL: BCBSA; November 2001; 16(14). Available at: http://www.bcbs.com/tec/vol16/16_14.html.Accessed April 7, 2004.
    30. Bredeson CN, Pavletic SZ. Considerations when designing a clinical trial of haematopoietic stem cell transplantation for autoimmune disease. Best Pract Res Clin Haematol. 2004;17(2):327-343.
    31. Passweg JR, Rabusin M, Musso M, et al. and the Autoimmune Disease Working Party of the EBMT. Haematopoetic stem cell transplantation for refractory autoimmune cytopenia. Br J Haematol. 2004;125(6):749-755.
    32. Jayne D, Passweg J, Marmont A, et al., and the European Group for Blood and Marrow Transplantation; European League Against Rheumatism Registry. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus. 2004;13(3):168-176.
    33. Raj A, Bertolone S, Cheerva A. Successful treatment of refractory autoimmune hemolytic anemia with monthly rituximab following nonmyeloablative stem cell transplantation for sickle cell disease. J Pediatr Hematol Oncol. 2004;26(5):312-314.
    34. Inglese M, Mancardi GL, Pagani E, et al. and the Italian GITMO-NEURO Group on Autologous Hematopoietic Stem Cell Transplantation. Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. J Neurol Neurosurg Psychiatry. 2004;75(4):643-644.
    35. Lisukov IA, Sizikova SA, Kulagin AD, et al. High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus. Lupus. 2004;13(2):89-94.
    36. Snowden JA, Passweg J, Moore JJ, et al. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: A report from the EBMT and ABMTR. J Rheumatol. 2004;31(3):482-488.
    37. Fassas A, Kazis A. High-dose immunosuppression and autologous hematopoietic stem cell rescue for severe multiple sclerosis. J Hematother Stem Cell Res. 2003;12(6):701-711.
    38. Grigg A, Tubridy NJ, Szer J, et al. Cladribine followed by autologous stem-cell transplantation in progressive multiple sclerosis. Intern Med J. 2004;34(1-2):66-69.
    39. Kishimoto T, Hamazaki T, Yasui M, et al. Autologous hematopoietic stem cell transplantation for 3 patients with severe juvenile rheumatoid arthritis. Int J Hematol. 2003;78(5):453-456.
    40. Fassas A, Kimiskidis VK. Stem cell transplantation for multiple sclerosis: What is the evidence? Blood Rev. 2003 Dec;17(4):233-240.
    41. Tyndall A, Matucci-Cerinic M. Haematopoietic stem cell transplantation for the treatment of systemic sclerosis and other autoimmune disorders. Expert Opin Biol Ther. 2003;3(7):1041-1049.
    42. Nash RA, Dansey R, Storek J, et al. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant. 2003;9(9):583-591.
    43. Marmont AM. Hematopoietic stem cell transplantation for severe and refractory lupus: comment on the article by Traynor et al. Arthritis Rheum. 2003;48(9):2696-2697;
    44. Burt RK, Traynor AE. SLE - hematopoietic stem cell transplantation for systemic lupus erythematosus. Arthritis Res Ther. 2003;5(5):207-109.
    45. Oyama Y, Traynor AE, Barr W, Burt RK. Allogeneic stem cell transplantation for autoimmune diseases: Nonmyeloablative conditioning regimens. Bone Marrow Transplant. 2003;32 Suppl 1:S81-S83.
    46. Nash RA. Allogeneic HSCT for autoimmune diseases: Conventional conditioning regimens. Bone Marrow Transplant. 2003;32 Suppl 1:S77-S80.
    47. Voltarelli JC, Ouyang J. Hematopoietic stem cell transplantation for autoimmune diseases in developing countries: Current status and future prospectives. Bone Marrow Transplant. 2003;32 Suppl 1:S69-S71.
    48. Wulffraat NM, Brinkman D, Ferster A, et al, Foster H, Abinun M, Prieur AM, et al. Long-term follow-up of autologous stem cell transplantation for refractory juvenile idiopathic arthritis. Bone Marrow Transplant. 2003;32 Suppl 1:S61-S64.
    49. Gratwohl A, Passweg J, Bocelli-Tyndall C, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant. 2005;35(9):869-879.
    50. Pluchino S, Martino G. The therapeutic use of stem cells for myelin repair in autoimmune demyelinating disorders. J Neurol Sci. 2005;233(1-2):117-119.
    51. Sykes M, Nikolic B. Treatment of severe autoimmune disease by stem-cell transplantation. Nature. 2005;435(7042):620-627.
    52. Kotter I, Daikeler T, Amberger C, et al. Autologous stem cell transplantation of treatment-resistant systemic vasculitis--a single center experience and review of the literature. Clin Nephrol. 2005;64(6):485-489.
    53. Jantunen E, Luosujarvi R. Stem cell transplantation in autoimmune diseases: An update. Ann Med. 2005;37(7):533-541.
    54. Griffith LM, Pavletic SZ, Tyndall A, et al. Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: Position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant. 2005;11(11):862-870.
    55. Alaez C, Loyola M, Murguia A, et al. Hematopoietic stem cell transplantation (HSCT): An approach to autoimmunity. Autoimmun Rev. 2006;5(3):167-179.
    56. Burt RK, Traynor A, Statkute L, et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA. 2006;295(5):527-535.
    57. Saccardi R, Kozak T, Bocelli-Tyndall C, et al; Autoimmune Diseases Working Party of EBMT. Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler. 2006;12(6):814-823.
    58. Loh Y, Oyama Y, Statkute L, et al. Autologous hematopoietic stem cell transplantation in systemic lupus erythematosus patients with cardiac dysfunction: Feasibility and reversibility of ventricular and valvular dysfunction with transplant-induced remission. Bone Marrow Transplant. 2007;40(1):47-53.
    59. Voltarelli JC, Couri CE, Stracieri AB, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007;297(14):1568-1576.
    60. Leung Y, Geddes M, Storek J, et al. Hematopoietic cell transplantation for Crohn's disease; is it time? World J Gastroenterol. 2006;12(41):6665-6673.
    61. U.S. Office of Veteran's Affairs, Office of Patient Care Services, Technology Assessment Unit. Bone marrow transplantation for treatment of multiple sclerosis. Bibliography. Boston, MA: Technology Assessment Unit, Office of Patient Care Services, US Department of Veterans Affairs (VATAP); 2006.
    62. Burt RK, Loh Y, Pearce W, et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA. 2008;299(8):925-936.
    63. Palma CA, Lindeman R, Tuch BE. Blood into beta-cells: Can adult stem cells be used as a therapy for Type 1 diabetes? Regen Med. 2008;3(1):33-47.
    64. Seissler J, Schott M. Generation of insulin-producing beta cells from stem cells--perspectives for cell therapy in type 1 diabetes. Horm Metab Res. 2008;40(2):155-161.
    65. Nikolov NP, Pavletic SZ. Technology Insight: Hematopoietic stem cell transplantation for systemic rheumatic disease. Nat Clin Pract Rheumatol. 2008;4(4):184-191.
    66. Marmont AM. Will hematopoietic stem cell transplantation cure human autoimmune diseases? J Autoimmun. 2008;30(3):145-150.
    67. van Laar JM, Farge D, Tyndall A. Stem cell transplantation: A treatment option for severe systemic sclerosis? Ann Rheum Dis. 2008;67 Suppl 3:iii35-iii38.
    68. Nikolov NP, Pavletic SZ. Technology Insight: Hematopoietic stem cell transplantation for systemic rheumatic disease. Nat Clin Pract Rheumatol. 2008;4(4):184-191.
    69. Schippling S, Martin R. Stem cell therapy in multiple sclerosis: A clinical update. Z Rheumatol. 2009;68(3):214-215, 217-219.
    70. Mobasheri A, Csaki C, Clutterbuck AL, et al. Mesenchymal stem cells in connective tissue engineering and regenerative medicine: Applications in cartilage repair and osteoarthritis therapy. Histol Histopathol. 2009;24(3):347-366.
    71. Burt RK, Loh Y, Cohen B, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: A phase I/II study. Lancet Neurol. 2009;8(3):244-253.
    72. Daikeler T, Hügle T, Farge D, et al; Working Party Autoimmune Diseases of the EBMT. Allogeneic hematopoietic SCT for patients with autoimmune diseases. Bone Marrow Transplant. 2009;44(1):27-33.
    73. Mundy L, Hiller J. Autologous haematopoietic stem cell transplantation (HSCT) for the regeneration of insulin-producing pancreatic cells in type 1 diabetics. Horizon Scanning Prioritising Summary. Adelaide, SA: Adelaide Health Technology Assessment; March 2010.
    74. Tappenden P, Saccardi R, Confavreux C, et al. Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: An exploratory cost-effectiveness analysis. Bone Marrow Transplant. 2010;45(6):1014-1021.
    75. Matthews JH, Smith CA, Herst J, et al.; Hematology Disease Site Group. The management of malignant thrombocytosis in Philadelphia chromosome-negative myeloproliferative disease: Guideline recommendations. Toronto, ON: Cancer Care Ontario (CCO); January 15, 2008.
    76. Cario H, McMullin MF, Pahl HL. Clinical and hematological presentation of children and adolescents with polycythemia vera. Ann Hematol. 2009;88(8):713-719.
    77. Atkins H. Hematopoietic SCT for the treatment of multiple sclerosis. Bone Marrow Transplant. 2010;45(12):1671-1681.
    78. Wagner JE, Ishida-Yamamoto A, McGrath JA, et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med. 2010;363(7):629-639.
    79. Du H, Lim SL, Grob S, Zhang K. Induced pluripotent stem cell therapies for geographic atrophy of age-related macular degeneration. Semin Ophthalmol. 2011;26(3):216-224.
    80. Huang Y, Enzmann V, Ildstad ST. Stem cell-based therapeutic applications in retinal degenerative diseases. Stem Cell Rev. 2011 Jun;7(2):434-445.
    81. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: Molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29(5):573-582.
    82. National Health, Lung and Blood Institute (NHLBI). Polycythemia vera. Diseases and Conditions Index. Bethesda, MD: National Institutes for Health (NIH); revised March 2011. Available at: http://www.nhlbi.nih.gov/health/dci/Diseases/poly/poly_treatments.html. Accessed July 12, 2011.
    83. Song XN, Lv HY, Sun LX, et al. Autologous stem cell transplantation for systemic lupus erythematosus: Report of efficacy and safety at 7 years of follow-up in 17 patients. Transplant Proc. 2011;43(5):1924-1927.
    84. Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): An open-label, randomised phase 2 trial. Lancet. 2011;378(9790):498-506.
    85. Reston JT, Uhl S, Treadwell JR, et al. Autologous hematopoietic cell transplantation for multiple sclerosis: A systematic review. Multiple Sclerosis. 2011;17(2):204-213.
    86. Schwartz SD, Hubschman JP, Heilwell G, et al. Embryonic stem cell trials for macular degeneration: A preliminary report. Lancet. 2012;379(9817):713-720.
    87. Glass JD, Boulis NM, Johe K, et al. Lumbar intraspinal injection of neural stem cells in patients with ALS: Results of a phase I trial in 12 patients. Stem Cells. 2012;30(6):1144-1151.
    88. Snowden JA, Saccardi R, Allez M, et al. Haematopoietic SCT in severe autoimmune diseases: Updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2012;47(6):770-790.
    89. Martinez HR, Molina-Lopez JF, Alez-Garza MT, et al. Stem cell transplantation in amyotrophic lateral sclerosis patients. Methodological approach, safety, and feasibility. Cell Transplant. 2012;21(9):1899-1907.
    90. Kotlarz D, Beier R, Murugan D, et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: Implications for diagnosis and therapy. Gastroenterology. 2012;143(2):347-355.
    91. Muise AM, Snapper SB, Kugathasan S. The age of gene discovery in very early onset inflammatory bowel disease. Gastroenterology. 2012; 143(2):285-288.
    92. National Institute for Health and Clinical Excellence (NICE). Crohn's disease: Management in adults, children and young people. NICE Clinical Guideline No. 152. London, UK: National Institute for Health and Clinical Excellence (NICE); October 2012.
    93. Li Y, Tsai YT, Hsu CW, et al. Long-term safety and efficacy of human-induced pluripotent stem cell (iPS) grafts in a preclinical model of retinitis pigmentosa. Mol Med. 2012;18:1312-1319.
    94. Kaplan AA, George JN. Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed May 2013.
    95. Peppercorn MA, Farrell RJ. Management of severe ulcerative colitis. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed May 2013.
    96. Bousvaros A, Leichtner A, Burpee T. Treatment of ulcerative colitis in children and adolescents. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed May 2013.
    97. Rice CM, Kemp K, Wilkins A, Scolding NJ. Cell therapy for multiple sclerosis: An evolving concept with implications for other neurodegenerative diseases. Lancet. 2013;382(9899):1204-1213.
    98. Wu KH, Wu HP, Chan CK, et al. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: From bench to bedsides. Cell Transplant. 2013;22(4):723-729.
    99. Batsali AK, Kastrinaki MC, Papadaki HA, Pontikoglou C. Mesenchymal stem cells derived from Wharton's Jelly of the umbilical cord: Biological properties and emerging clinical applications. Curr Stem Cell Res Ther. 2013;8(2):144-155.
    100. Thomsen GM, Gowing G, Svendsen S, Svendsen CN. The past, present and future of stem cell clinical trials for ALS. Exp Neurol. 2014;262 Pt B:127-137.
    101. Witkowska M, Smolewska E, Smolewski P. Hematopoietic stem cell transplantation in children with autoimmune connective tissue diseases. Arch Immunol Ther Exp (Warsz). 2014;62(4):319-327.
    102. Press R, Askmark H, Svenningsson A, et al. Autologous haematopoietic stem cell transplantation: A viable treatment option for CIDP. J Neurol Neurosurg Psychiatry. 2014;85(6):618-624.
    103. Al-toma A, Nijeboer P, Bouma G, et al. Hematopoietic stem cell transplantation for non-malignant gastrointestinal diseases. World J Gastroenterol. 2014;20(46):17368-17375.
    104. Liu B, Shu S, Kenny TP, et al. Stem cell therapy in autoimmune rheumatic diseases: A comprehensive review. Clin Rev Allergy Immunol. 2014;47(2):244-257.
    105. Burt RK, Balabanov R, Han X, et al.  Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. JAMA. 2015;313(3):275-284.
    106. Hauser SL. Hematopoietic stem cell transplantation for MS: Extraordinary evidence still needed. JAMA. 2015;313(3):251-252.
    107. Mancardi GL, Sormani MP, Gualandi F; ASTIMS Haemato-Neurological Collaborative Group, On behalf of the Autoimmune Disease Working Party (ADWP) of the European Group for Blood and Marrow Transplantation (EBMT); ASTIMS Haemato-Neurological Collaborative Group On behalf of the Autoimmune Disease Working Party ADWP of the European Group for Blood and Marrow Transplantation EBMT. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial. Neurology. 2015;84(10):981-988.


You are now leaving the Aetna website.

Links to various non-Aetna sites are provided for your convenience only. Aetna Inc. and its subsidiary companies are not responsible or liable for the content, accuracy, or privacy practices of linked sites, or for products or services described on these sites.

Continue >